Lyondell Judge Approves Plan to Exit Bankruptcy

 A bankruptcy court judge on Friday approved Lyondell Chemical's plan to exit bankruptcy, signaling the near-end of a 15-month process during which the chemical maker fended off a takeover and settled hundreds of environmental claims and a creditor lawsuit.

Judge Robert Gerber gave his assent to a plan in which Apollo Management, Ares Management and Access Industries will provide financing.

Lyondell filed for bankruptcy in January of 2009 under the weight of about $24 billion in debt. When asked by Lyondell before a packed courtroom after a day-long proceeding if he would approve the plan, Gerber said "yes" and then joked that he felt a bit like he was taking part in a marriage.

Lyondell presented the creditor-backed plan last month when it rejected a takeover bid from India's Reliance Industries, which valued the company at $14.5 billion, saying it was not high enough. Court documents show the company's investment bankers value Lyondell at $14.2 billion to $16.2 billion.

Under its stand-alone plan, the details of which were released in March, Lyondell plans to emerge from bankruptcy as Netherlands-based LyondellBasell, with $7.2 billion in debt and $2 billion in cash. The chemical company also will shed most environmental liabilities, many of which it settled in a $250 million agreement with the U.S. government and state governments.

Judge Gerber of Manhattan Federal bankruptcy court earlier on Friday approved that settlement.

After emerging from bankruptcy, which the company expects to do by April 30, the company will be partly owned by private equity firms Apollo and Ares as well as Access, an industrial holding company owned by investor Len Blavatnik, who will together back a $2.8 billion rights offering. In the rights offering, Apollo can invest up to $1.52 billion, Ares can invest up to $475.7 million and Access can invest up to $805.9 million.

Shares of the new company are expected to be listed on the New York Stock Exchange during the third quarter, its attorney George Davis of Cadwalader, Wickersham & Taft said during the hearing. Blavatnik created the original LyondellBasell in 2007 through a leveraged buyout of Lyondell, a largely U.S.-based company. He then combined the company with his Dutch chemicals company Basell AF SCA.

In March, Lyondell reached a $450 million settlement to resolve litigation over that buyout with creditors, who said that the $22 billion buyout had been designed to fail.

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.